Gout Drug Development Will Target Future Treatment Needs
A new clinical program aims to offer an alternative therapy for patients who cannot tolerate standard gout treatments.
Updated on Sept. 18, 2026 in Arthritis
Live Poll
Should pharmaceutical companies prioritize developing new treatments for common conditions like gout?
XORTX Therapeutics plans to submit an Investigational New Drug application in late 2026 for XRx-026, a proprietary gout treatment program. The development follows growing prevalence rates for the condition, which affects 9.2 million people in the United States.
Why it matters
The program seeks to provide a new therapeutic option for the estimated 3 to 5 percent of patients who are unable to tolerate allopurinol. Developing alternative treatments is increasingly critical as global gout cases are expected to rise by 70 percent over the next 25 years.
XORTX Therapeutics is preparing for a two-part clinical study to evaluate the pharmacokinetics and efficacy of XORLO, a proprietary formulation of oxypurinol. The trials aim to establish clinical data for this potential treatment before moving toward an New Drug Application.
The players
XORTX Therapeutics
A clinical pharmaceutical company focused on developing therapies for kidney health and inflammatory conditions.
The details
The XRx-026 program centers on XORLO, which is a proprietary formulation of the drug oxypurinol. It is designed to function as a xanthine oxidase inhibitor, a class of medication that works by reducing the production of uric acid in the body. By inhibiting this enzyme, the drug aims to help manage the levels of uric acid that lead to gout symptoms.
Timeline
XORTX plans to submit an IND application to the FDA in the fourth quarter of 2026.
The company targets a New Drug Application submission for September 2027.
Global gout cases are projected to increase 70 percent over the next 25 years.
Health Landscape
The gout treatment market is anchored by established xanthine oxidase inhibitors like febuxostat, which previously reached peak annual sales of over $450 million. This new program aims to carve out a share of an estimated $700 million annual opportunity by offering a differentiated profile.
If you have been diagnosed with gout and experience side effects or intolerance to current medications like allopurinol, it is worth discussing alternative treatment options with your physician. Staying informed about new therapeutic developments can help you participate in upcoming care decisions.
The takeaway
As gout prevalence continues to climb, research is increasingly focused on finding alternatives for patients who cannot tolerate traditional enzyme inhibitors. Keep track of your uric acid levels and consult your rheumatologist about the latest treatment guidelines that may apply to your care.
Further reading
For more information on managing chronic joint pain, visit our Arthritis section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should pharmaceutical companies prioritize developing new treatments for common conditions like gout?
